- Home
- CYBN vs SLS Comparison
CYBN vs SLS Comparison
Compare CYBN & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- SLS
- Stock Information
- Founded
- CYBN 2019
- SLS 2012
- Country
- CYBN Canada
- SLS United States
- Employees
- CYBN N/A
- SLS N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- SLS Health Care
- Exchange
- CYBN Nasdaq
- SLS Nasdaq
- Market Cap
- CYBN 180.4M
- SLS 169.6M
- IPO Year
- CYBN N/A
- SLS N/A
- Fundamental
- Price
- CYBN $7.61
- SLS $1.85
- Analyst Decision
- CYBN Strong Buy
- SLS
- Analyst Count
- CYBN 4
- SLS 0
- Target Price
- CYBN $85.00
- SLS N/A
- AVG Volume (30 Days)
- CYBN 387.1K
- SLS 3.6M
- Earning Date
- CYBN 08-07-2025
- SLS 08-12-2025
- Dividend Yield
- CYBN N/A
- SLS N/A
- EPS Growth
- CYBN N/A
- SLS N/A
- EPS
- CYBN N/A
- SLS N/A
- Revenue
- CYBN N/A
- SLS N/A
- Revenue This Year
- CYBN N/A
- SLS N/A
- Revenue Next Year
- CYBN N/A
- SLS N/A
- P/E Ratio
- CYBN N/A
- SLS N/A
- Revenue Growth
- CYBN N/A
- SLS N/A
- 52 Week Low
- CYBN $4.81
- SLS $0.77
- 52 Week High
- CYBN $13.88
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- CYBN 46.51
- SLS 52.48
- Support Level
- CYBN $7.35
- SLS $1.88
- Resistance Level
- CYBN $7.85
- SLS $2.27
- Average True Range (ATR)
- CYBN 0.60
- SLS 0.17
- MACD
- CYBN -0.10
- SLS -0.00
- Stochastic Oscillator
- CYBN 18.20
- SLS 52.60
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.